Teva Pharmaceutical Industries (TEVJF) Cost of Revenue (2016 - 2026)

Teva Pharmaceutical Industries has disclosed Cost of Revenue across 11 years of filings, most recently posting $696.0 million for Q1 2026.

• Quarterly Cost of Revenue rose 11.9% year-over-year to $696.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 billion (down 39.3% YoY) and the FY2025 annual result came in at $8.3 billion, down 1.9% from the prior year.
• Cost of Revenue slipped to $696.0 million in Q1 2026, from $2.1 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $6.6 billion in Q4 2024 and troughed at $539.0 million in Q3 2022.
• A 5-year average of $1.9 billion and a median of $2.1 billion in 2025 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue slumped 71.13% — and 2024, when it soared 980.33%.
• Tracing TEVJF's Cost of Revenue over 5 years: stood at $2.1 billion in 2022, then sank by 71.13% to $610.0 million in 2023, then surged by 980.33% to $6.6 billion in 2024, then tumbled by 68.8% to $2.1 billion in 2025, then tumbled by 66.15% to $696.0 million in 2026.
• Business Quant data shows TEVJF's Cost of Revenue at $696.0 million in Q1 2026, $2.1 billion in Q4 2025, and $2.2 billion in Q3 2025.